Table 2.
Comparison of baseline characteristics with PARADIGM‐HF sacubitril/valsartan arm
| Variable | Real world (n = 120) | Sacubitril/valsartan arm (n = 4187) | P‐value |
|---|---|---|---|
| Demographics | |||
| Age, years | 66.0 ± 10.5 | 63.8 ± 11.5 | 0.038 |
| Male | 98 (81%) | 3308 (79%) | 0.480 |
| Heart failure aetiology | 0.159 | ||
| Ischaemic | 80 (66.6%) | 2506 (59.9%) | |
| Non‐ischaemic | 40 (33.3%) | 1681 (40.1%) | |
| Physical features | |||
| Systolic blood pressure, mmHg | 120 ± 20 | 122 ± 15 | 0.154 |
| BMI, kg/m2 | 28.9 ± 9.0 | 28.1 ± 5.5 | 0.125 |
| Heart rate, b.p.m. | 69 ± 15 | 72 ± 12 | 0.007 |
| Co‐morbidities | |||
| Atrial fibrillation | 51 (42%) | 1517 (36%) | 0.159 |
| Hypertension | 56 (46%) | 2969 (71%) | <0.001 |
| Diabetes | 29 (24%) | 1451 (35%) | 0.017 |
| Laboratory analysis | |||
| Serum creatinine, mg/dL | 1.28 ± 0.4 | 1.13 ± 0.3 | <0.001 |
| NYHA class | 0.013 | ||
| Class I | 0 (0%) | 180 (4.3%) | |
| Class II | 76 (63.5%) | 2998 (71.6%) | |
| Class III | 43 (35.5%) | 969 (23.1%) | |
| Class IV | 1 (1%) | 33 (0.8%) | |
| Echocardiography | |||
| LVEF, % | 26 ± 6 | 29 ± 6 | <0.001 |
| Heart failure therapies | |||
| ACE‐I | 98 (82%) | 3266 (78%) | 0.480 |
| ARB | 22 (18%) | 929 (22%) | 0.316 |
| Beta‐blocker | 115 (95%) | 3899 (93%) | 0.520 |
| Aldosterone antagonist | 99 (82%) | 2271 (54%) | <0.001 |
| Loop diuretic | 72 (60%) | 3363 (80%) | <0.001 |
| CRT | 52 (43%) | 292 (7%) | <0.001 |
| ICD | 67 (55%) | 623 (15%) | <0.001 |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.